The October 2020 issue of Pharmafocus is available to read free online now!
pharmafile | September 29, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | 2020, October 2020, Pharmafocus, digital edition, pharma
The latest monthly edition of Pharmafocus is available to read for free online now!
As the US sails past the grim milestone of 200,000 deaths as a result of COVID-19, the projected arrival date of a vaccine has been subject to a lot of mixed messaging from the CDC and President Trump himself. And as November’s presidential election grows closer, new survey data indicates that as much as two-thirds of US citizens expect regulators to bow to political pressure and approve a vaccine before it has been properly tested. This could have significant consequences for the nation’s pandemic response – you can read more on our front page.
Across the world, Russia is chalking up delivery deals for its own vaccine, the controversial homegrown therapy Sputnik V. So far, the country has promising to deliver doses to India, Mexico and parts of Brazil, with studies ongoing to better prove its safety and efficacy in fighting the novel coronavirus. We cover the full story on page 11.
AstraZeneca’s COVID-19 vaccine, currently in development in partnership with the University of Oxford, has emerged as one of the front runners in the race for an effective prophylactic therapy to prevent infection with the novel coronavirus. But a mystery illness in one of the participants put the brakes on international trials for the treatment. You can read the full story on page 8.
Elsewhere in the issue, BioInvent CEO Martin Welschof looks back on his numerous leadership roles to share the key traits that helped him find success in our regular Working Life, and in this month’s opinion piece, Anthony Brennand, Director of Innovation at IP technology firm CPA Global, explains why artificial intelligence could be the cornerstone of efforts to supercharge drug discovery efforts in the wake of the global pandemic crisis.
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
